Kent C. Shih

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman, Jeffery S. Russell, Omid Hamid et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +11

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

Howard L. Kaufman, Jeffery S. Russell, Omid Hamid et al. · Journal for ImmunoTherapy of Cancer · 2018 · 330 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues et al. · Clinical Cancer Research · 2018 · 310 citations

Medicine, Oncology, Pharmacology +15

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

Sandra P. D’Angelo, Shailender Bhatia, Andrew S. Brohl et al. · Journal for ImmunoTherapy of Cancer · 2020 · 197 citations · Full text

Medicine, Oncology, Pharmacology +17